Cognitive behavioural therapy for insomnia (CBT-I)
Everything filed under diagnostico y tratamiento clinico in our sleep coverage, the 10 reports filed on it so far.
Exercise Slows Aging, Boosts Memory in Breast Cancer
A 12-month exercise program improved memory and slowed epigenetic aging in breast cancer survivors, though cognitive gains faded after one year.
My CPAP Caddy Bedside Stand Aims to Improve Therapy
An inventor has launched an adjustable bedside stand designed to organize CPAP equipment and address common frustrations like tangled hoses and
Cognitive Behavioral Therapy Slows Aging in Insomnia
A UCLA study found that cognitive behavioral therapy for insomnia in older adults not only improved sleep but also slowed the pace of biological...
Facial Hair Poses CPAP Mask Fitting Challenge, Survey Finds
A survey of sleep professionals finds 41% identify patients with facial hair as the hardest to fit for CPAP therapy.
TOMAC Therapy for Restless Legs Syndrome
Tonic motor activation (TOMAC) is a noninvasive, wearable electrical stimulation therapy for moderate to severe restless legs syndrome.
Psilocybin therapy faces palliative care
A Canadian survey finds most palliative care professionals favor psilocybin therapy for end-of-life distress but feel ill-informed and cite a...
CPAP Store USA Expands Sleep Therapy Options with Inogen Aurora CPAP Mask Line
CPAP Store USA has partnered with Inogen to offer the Inogen Aurora CPAP Mask Collection nationwide, providing consumers with a new range of...
ICER Report Evaluates Clinical Value of New Narcolepsy Type 1 Treatment
The Institute for Clinical and Economic Review (ICER) has published a final evidence report on oveporexton, a novel orexin receptor 2 agonist for...
New Study Finds Vivos Oral Appliance Reduces Insomnia Severity in 100% of Participants
A recent study has shown that the Vida oral appliance, developed by Vivos Therapeutics Inc, can significantly reduce insomnia severity in patients...
DEA Proposes Rescheduling DORAs for Insomnia Treatment
The US Drug Enforcement Administration (DEA) has proposed transferring three dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V...